Federal Supply Schedule 36F79719D0205
Award Date
8/15/19
Last Date to Order
9/14/25
Federal Agency
Veterans Integrated Service Network 12
Awardee
Jazz Pharmaceuticals, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs National Acquisition Center awarded a Blanket Purchase Agreement (BPA) to Jazz Pharmaceuticals, Inc. for the delivery of specialty pharmaceutical products, primarily the sleep disorder medication Xyrem. The $150 million BPA is issued under Jazz Pharmaceuticals' Pharmaceuticals and Drugs Federal Supply Schedule (FSS) contract, allowing the VA to efficiently procure needed medications for its healthcare facilities. Four task orders worth up to $717,519 have...
The Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) to Jazz Pharmaceuticals, Inc., a global biopharmaceutical company, to provide specialty pharmaceutical products such as Xyrem, Xywav, and sodium oxybate formulations. The BPA, valued at up to $150 million, allows the VA to efficiently procure needed medications to support healthcare services for veterans at VA medical facilities nationwide....
This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Jazz Pharmaceuticals, Inc. as the prime contractor. The BPA is valued at $161,183,457.45 and has an ultimate completion date of August 15, 2025. The purpose of this BPA is to provide the VA with access to Jazz Pharmaceuticals' specialty pharmaceuticals, including Xyrem and Xywav, through an efficient procurement vehicle. Four call...
The Department of Veterans Affairs (VA) has awarded a $1.7 million Federal Supply Schedule (FSS) contract to Amneal Pharmaceuticals of New York, LLC for the supply of drugs, pharmaceuticals, and hematology-related products under the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule. The contract has an ultimate completion date of June 30, 2027. Additionally, the VA has issued two firm fixed-price delivery orders to Amneal Pharmaceuticals under the FSS contract, totaling $359,000. These orders...
The U.S. Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) worth up to $2,500,000 to Amneal Pharmaceuticals of New York, LLC, a for-profit limited liability company that manufactures pharmaceutical products. The BPA is for the provision of the generic drug sodium oxybate, which is used to treat narcolepsy. Amneal Pharmaceuticals holds several indefinite delivery vehicle (IDV) contracts with federal agencies, including a 5-year, $1,700,000 Federal Supply...
The Department of Veterans Affairs (VA) awarded Xeris Pharmaceuticals, Inc., a small disadvantaged business manufacturer, a multiple-award Federal Supply Schedule (FSS) contract under FSS-61-IB for Pharmaceuticals and Drugs. The $4,119,200 contract has a period of performance from July 2020 to July 2025, allowing the VA's Integrated Service Network 12 to procure a range of Xeris' drug therapies, pharmaceuticals, and hematology products to support healthcare operations for veteran patients....
The Department of Veterans Affairs (VA) Veterans Health Administration awarded Lundbeck LLC a 5-year Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs with a potential value of $124 million. Through this contract vehicle, the VA and other federal agencies can procure Lundbeck's portfolio of medications used to treat neurological conditions prevalent among veterans, including Sabril (vigabatrin) for treatment-resistant seizures, Xenazine (tetrabenazine) for chorea...
The Department of Veterans Affairs (VA) has awarded a series of contracts and agreements to Harmony Biosciences LLC, a pharmaceutical company specializing in rare neurological diseases and sleep disorders, to provide the medication WAKIX (pitolisant). Harmony Biosciences holds a $5 million Blanket Purchase Agreement (BPA) with the VA National Acquisition Center and a $259,000 multiple award indefinite-delivery indefinite-quantity (IDIQ) contract with the VA Veterans Health Administration to...
Hikma Pharmaceuticals USA Inc., a foreign-owned, for-profit pharmaceutical manufacturer, holds a $216 million Federal Supply Schedule contract (FSS-61-IB) with the Department of Veterans Affairs (VA) for the procurement of pharmaceuticals and drugs. This multiple-award, unrestricted Indefinite Delivery Vehicle (IDV) enables Hikma to provide a wide range of pharmaceutical products, including injectable solutions, tablets, and specialized medications, to military treatment facilities, VA...
Janssen Products LP, a subsidiary of Johnson & Johnson, holds a multiple award Federal Supply Schedule (FSS-61-IB) contract for pharmaceutical products awarded by the U.S. Department of Veterans Affairs (VA). The contract has a potential value of $881 million through July 2025. Under this IDV, Janssen provides the VA with critical medications such as Sirturo (bedaquiline), an antitubercular drug, and Balversa (erdafitinib), an oncology treatment. Task orders are primarily awarded by...